Loading
A phase 2 trial of Dostarlimab in head and neck squamous cell carcinoma, run by GlaxoSmithKline, active and no longer recruiting.
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 is a phase 2 interventional study registered as NCT06062420 by GlaxoSmithKline, with 316 participants enrolled, started 2023-11-14 and due to reach its primary completion in 2026-09-01. Interventions recorded: Dostarlimab, Belrestotug, Nelistotug and Remzistotug.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Head and neck squamous cell carcinoma and the tag pipeline.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/